

Haematologica
HAEMATOL/2018/192492
Version 3

End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted-EPOCH-R: A paradigm shift in clinical decision making

Christopher Melani, Ranjana Advani, Mark Roschewski, Kelsey M. Walters, Clara C. Chen, Lucia Baratto, Mark A. Ahlman, Milos D. Miljkovic, Seth M. Steinberg, Jessica Lam, Margaret Shovlin, Kieron Dunleavy, Stefania Pittaluga, Elaine S. Jaffe, and Wyndham H. Wilson

Disclosures: Advani: Gilead: Consultancy; Nanostring: Consultancy; Kyowa Hakko Kirin: Consultancy, Honoraria; Infinity: Research Funding; FortySeven: Consultancy, Honoraria; Genentech: Consultancy, Honoraria, Research Funding; Sutro: Consultancy, Honoraria; Spectrum: Consultancy, Honoraria; BMS: Consultancy, Honoraria, Research Funding; Juno: Consultancy, Honoraria; Stanford University: Employment; Millennium: Research Funding; Kura: Research Funding; Celgene: Research Funding; Regeneron: Research Funding; Merck: Research Funding; Pharmacoclics: Research Funding; Janssen: Research Funding; Seattle Genetics: Research Funding; Bayer: Research Funding; Cell Medica: Research Funding; Agensys: Research Funding. Milos D. Miljkovic: Pfizer: Research Funding. Dunleavy: Celgene: Consulting; Abbvie: Consulting; Karyopharm: Consulting; Adaptive: Consulting. All other authors declare no competing financial interests.

Contributions: C.M. treated, analyzed the data, and wrote the manuscript; R.A., M.R., and K.D. treated, analyzed the data, and reviewed the manuscript; K.M.W., J.L., C.C.C., L.B., S.M.S., M.A.A., M.D.M., and M.S. analyzed the data, and reviewed the manuscript; S.P. and E.S.J. performed pathology, analyzed the data, and reviewed the manuscript; W.H.W. conceived and conducted the study, analyzed the data, and helped write the manuscript.